Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 1921 AL 1935

Comparative Bioavailability Study of a Novel Multi-Day Patch Formulation of Rivastigmine (Twice Weekly) with Exelon® Transdermal Patch (Daily)- A Randomized Clinical Trial

Schurad B, Koch C, Schug B, Morte A, Vaqué A, De la Torre R, Iniesta M.

Curr Alzheimer Res. 2022;19(7):541-553. doi: 10.2174/1567205019666220823105059.

Quantitative trait locus (xQTL) approaches identify risk genes and drug targets from human non-coding genomes

Bykova M, Hou Y, Eng C, Cheng F.

Hum Mol Genet. 2022 Oct 20;31(R1):R105-R113. doi: 10.1093/hmg/ddac208.

TFEB in Alzheimer's disease: From molecular mechanisms to therapeutic implications

Gu Z, Cao H, Zuo C, Huang Y, Miao J, Song Y, Yang Y, Zhu L, Wang F.

Neurobiol Dis. 2022 Oct 15;173:105855. doi: 10.1016/j.nbd.2022.105855. Epub 2022 Aug 27.

γ-Secretase as a drug target for familial Alzheimer's disease: the road less traveled

Wolfe MS.

Future Med Chem. 2022 Oct;14(19):1341-1343. doi: 10.4155/fmc-2022-0178. Epub 2022 Aug 30.

Carthamus tinctorius L.: A natural neuroprotective source for anti-Alzheimer's disease drugs

Liang Y, Wang L.

J Ethnopharmacol. 2022 Nov 15;298:115656. doi: 10.1016/j.jep.2022.115656. Epub 2022 Aug 27.

Neuroinflammation and Oxidative Stress in Alzheimer's Disease; Can Nutraceuticals and Functional Foods Come to the Rescue?

Onaolapo OJ, Olofinnade AT, Ojo FO, Onaolapo AY.

Antiinflamm Antiallergy Agents Med Chem. 2022;21(2):75-89. doi: 10.2174/1871523021666220815151559.

Recent advance on pleiotropic cholinesterase inhibitors bearing amyloid modulation efficacy

Zhang H, Peng Y, Zhuo L, Wang Y, Zeng G, Wang S, Long L, Li X, Wang Z.

Eur J Med Chem. 2022 Nov 15;242:114695. doi: 10.1016/j.ejmech.2022.114695. Epub 2022 Aug 27.

Toll-Like Receptor 4: A Promising Therapeutic Target for Alzheimer's Disease

Wu L, Xian X, Xu G, Tan Z, Dong F, Zhang M, Zhang F.

Mediators Inflamm. 2022 Aug 21;2022:7924199. doi: 10.1155/2022/7924199. eCollection 2022.

Targeting Novel microRNAs in Developing Novel Alzheimer's Disease Treatments

Seyedaghamiri F, Rajabi M, Mohaddes G.

Neurochem Res. 2023 Jan;48(1):26-38. doi: 10.1007/s11064-022-03734-6. Epub 2022 Sep 1.

Ever-expanding landscape: Alzheimer's - new targets and new patents

Egunlusi AO, Joubert J.

Pharm Pat Anal. 2022 Sep;11(5):135-138. doi: 10.4155/ppa-2022-0031. Epub 2022 Sep 2.

Targeted Mitochondrial Epigenetics: A New Direction in Alzheimer's Disease Treatment

Song Y, Zhu XY, Zhang XM, Xiong H.

Int J Mol Sci. 2022 Aug 26;23(17):9703. doi: 10.3390/ijms23179703.

The Impairment of Blood-Brain Barrier in Alzheimer's Disease: Challenges and Opportunities with Stem Cells

López-Ornelas A, Jiménez A, Pérez-Sánchez G, Rodríguez-Pérez CE, Corzo-Cruz A, Velasco I, Estudillo E.

Int J Mol Sci. 2022 Sep 4;23(17):10136. doi: 10.3390/ijms231710136.

Combination Therapy for the Treatment of Alzheimer's Disease: Recent Progress and Future Prospects

Shirbhate E, Patel VK, Tiwari P, Kore R, Veerasamy R, Mishra A, Rajak H.

Curr Top Med Chem. 2022;22(22):1849-1867. doi: 10.2174/1568026622666220907114443.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias